ATE298367T1 - Interleukin-15 antagoniste - Google Patents

Interleukin-15 antagoniste

Info

Publication number
ATE298367T1
ATE298367T1 AT97922455T AT97922455T ATE298367T1 AT E298367 T1 ATE298367 T1 AT E298367T1 AT 97922455 T AT97922455 T AT 97922455T AT 97922455 T AT97922455 T AT 97922455T AT E298367 T1 ATE298367 T1 AT E298367T1
Authority
AT
Austria
Prior art keywords
interleukin
antagonist
polypeptides
mutant
modulate
Prior art date
Application number
AT97922455T
Other languages
English (en)
Inventor
Terry Strom
Wlodzimerz Maslinski
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE298367T1 publication Critical patent/ATE298367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97922455T 1996-04-26 1997-04-25 Interleukin-15 antagoniste ATE298367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1663496P 1996-04-26 1996-04-26
PCT/US1997/006931 WO1997041232A1 (en) 1996-04-26 1997-04-25 Antagonists of interleukin-15

Publications (1)

Publication Number Publication Date
ATE298367T1 true ATE298367T1 (de) 2005-07-15

Family

ID=21778153

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97922455T ATE298367T1 (de) 1996-04-26 1997-04-25 Interleukin-15 antagoniste

Country Status (8)

Country Link
US (1) US6001973A (de)
EP (1) EP0927254B1 (de)
JP (1) JP2001502521A (de)
AT (1) ATE298367T1 (de)
CA (1) CA2252557A1 (de)
DE (1) DE69733610T2 (de)
ES (1) ES2243995T3 (de)
WO (1) WO1997041232A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
ATE368108T1 (de) 1998-01-22 2007-08-15 Btg Int Ltd Hemmung der cytokin-herstellung
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US20030013668A1 (en) * 1998-07-07 2003-01-16 Dange Veerapanane Ph.D Antisense oligonucleotides targeted to il-15
GB9814892D0 (en) * 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
AU6689700A (en) * 1999-07-06 2001-01-22 Silvia Bulfone-Paus Method of treating psoriasis with il-15 antagonist
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0110779A (pt) * 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
JP2004525076A (ja) 2000-09-14 2004-08-19 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド Ｉｌ−２およびｉｌ−１５媒介ｔ細胞応答の調節
US20060134140A1 (en) * 2001-04-12 2006-06-22 Dana Lasko Compositions and methods for treating tumor spreading
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
WO2003007685A2 (en) 2001-07-17 2003-01-30 University Of Florida Detecting and treating reproductive tract disorders
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
AU2002332628B2 (en) * 2001-08-23 2007-07-26 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US6800462B2 (en) * 2001-09-10 2004-10-05 Abgenomics Corporation Production of recombinant proteins in vivo and use for generating antibodies
US20030049694A1 (en) * 2001-09-10 2003-03-13 Chung-Hsiun Wu Production of fusion proteins and use for identifying binding molecules
BR0315327A (pt) * 2002-10-14 2005-08-16 Hoffmann La Roche Antagonistas de il-15
CN100427597C (zh) * 2003-11-26 2008-10-22 中国医学科学院基础医学研究所 可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法
JP5744369B2 (ja) * 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
JP2007538006A (ja) * 2004-04-14 2007-12-27 エフ．ホフマン−ラ　ロシュ　アーゲー 精製インターロイキン１５／Ｆｃ融合タンパク質とその調整
JP2005309295A (ja) * 2004-04-26 2005-11-04 Nec Corp 光増幅素子、光増幅装置および光増幅システム
WO2006017853A2 (en) * 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15-containing compositions and suppression of an immune response
CU23472A1 (es) * 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
EP1807109A2 (de) * 2004-10-05 2007-07-18 Ochsner Clinic Foundation Verstärkung der proliferation von b-zellen durch il-15
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
CA2611946C (en) * 2005-06-20 2013-04-16 Cadila Healthcare Limited Expression vector and methods of producing high levels of proteins
EP1777294A1 (de) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
EP1921452A1 (de) * 2006-11-08 2008-05-14 Medizinische Hochschule Hannover Methode zur Diagnose von Leukämie
WO2008138017A2 (en) * 2007-05-08 2008-11-13 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
CA2690825C (en) * 2007-05-11 2019-02-12 Altor Bioscience Corporation Fusion molecules and il-15 variants
NZ599338A (en) 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
CU23716A1 (es) 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
WO2011012297A1 (en) 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Enzymatic antibody processing
CA2768965C (en) 2009-08-14 2019-06-04 George N. Pavlakis Use of il-15 to increase thymic output and to treat lymphopenia
KR20140020228A (ko) 2010-09-21 2014-02-18 알토 바이오사이언스 코포레이션 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
SG10201605397PA (en) 2011-07-01 2016-08-30 Hoffmann La Roche Method For Separation Of Monomeric Polypeptides From Aggregated Polypeptides
DK2986312T3 (da) 2013-04-19 2022-02-14 Cytune Pharma Cytokinafledt behandling med reduceret vaskulært lækagesyndrom
SG10202010429YA (en) * 2013-07-19 2020-11-27 Vib Vzw Targeting of cytokine antagonists
KR101440915B1 (ko) 2014-03-31 2014-09-18 공주대학교 산학협력단 개 인터루킨-15 체외 증폭용 프라이머 세트, 이의 용도 및 이를 이용한 재조합 개 인터루킨-15 제조방법
US9925247B2 (en) 2014-06-30 2018-03-27 Altor Bioscience Corporation IL-15-based molecules and methods of use thereof
EP3206713A4 (de) * 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15-zusammensetzungen und verwendungen davon
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
SG11201903306SA (en) 2016-10-21 2019-05-30 Altor Bioscience Corp Multimeric il-15-based molecules
CU24546B1 (es) 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
KR20190142775A (ko) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
EP3678701A4 (de) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Therapeutische proteinzusammensetzungen und verfahren zur herstellung und verwendung davon
CU24545B1 (es) 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
EP3781599A1 (de) 2018-04-18 2021-02-24 Xencor, Inc. Auf pd-1 abgezielte heterodimere fusionsproteine mit il-15-/il-15ra-fc-fusionsproteinen und pd-1-antigen-bindenden domänen und verwendungen davon
MX2021004059A (es) 2018-10-12 2021-09-23 Xencor Inc Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
KR102265430B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2186747C (en) * 1994-04-06 2009-01-27 Kenneth H. Grabstein Interleukin-15
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15

Also Published As

Publication number Publication date
JP2001502521A (ja) 2001-02-27
EP0927254A1 (de) 1999-07-07
WO1997041232A1 (en) 1997-11-06
CA2252557A1 (en) 1997-11-06
ES2243995T3 (es) 2005-12-01
DE69733610T2 (de) 2006-05-11
DE69733610D1 (de) 2005-07-28
EP0927254B1 (de) 2005-06-22
US6001973A (en) 1999-12-14

Similar Documents

Publication Publication Date Title
ATE298367T1 (de) Interleukin-15 antagoniste
ATE360032T1 (de) Cystein-reiche rezeptoren-train
DE69634739D1 (de) Höhenverstellbares armlehnengefüge
AU124792S (en) Bowl
FI972105A0 (fi) Jauhetun hiilen poltin
DK245689A (da) Bacillus thuringiensis transformationer
FI964214A (fi) Parannuksia kitkatulpan puristukseen
TR199900509T2 (xx) Omeprazol haz�rlanmas� i�in y�ntem.
DE29617010U1 (de) Schreibunterlage
KR970004061U (ko) 의자 높.낮이 조절장치
KR970056725U (ko) 학생용 의자 시트
AT995U3 (de) Schülersessel
DE29602363U1 (de) Liege- und Sitzunterlage
DE29815236U1 (de) Schülersessel
KR960000286U (ko) 가구의 수평 조절 장치
SE8800691D0 (sv) Sittmobel for utomhusbruk
KR980000499U (ko) 의자용 팔걸이
DE29621743U1 (de) Schulterauflage
KR910010673U (ko) 벽걸이용 t.v. 받침대
KR930022884U (ko) 휴대용 의자
KR920000985U (ko) 침실의 조명장치용 음향 발생유니트
LV10395A (lv) Bezsapju vakcinas sastavs
BR7102489U (pt) Banco modulado portatil
DK0927254T3 (da) Interleukin-15-antagonister
SE8800071D0 (sv) Koppling for mobel- och inredningsdelar

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0927254

Country of ref document: EP

REN Ceased due to non-payment of the annual fee